Resent studies on cytochrome P450 and drug metabolism

Abstract

Abstract: Cytochrome P450 is one of the important drug metabolization enzymes in humans. This paper reviews drug-relevant CYP, the relationship of CYP and drug interaction, and effects of Chinese medicine on CYP. The aim is to answer and predict the clinical drug interaction and the adverse drug reactions. Moreover, suitable drug can be selected to evaluate the action of CYP, and it can offer the scientific assurance for clinical individual therapy.

Key words: cytochrome P450, Chinese medicine, drug interaction, drug metabolism

CLC Number:

R966

ZHU Li-Qin, LOU Jian-Shi. Resent studies on cytochrome P450 and drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1081-1086.

References

1 Estabrook RW.A passion for P450s(rememberances of the early history of research on cytochrome P450)[J]. Drug Metab Dispos, 2003;31(12):1461-73
2 Kivisto KT, Kroemer HK.Use of probe drugs as predictors of drug metabolism in humans[J]. J Clin Pharmacol, 1997;37 (Suppl 1):40-8
3 Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J]. Eur J Clin Invest, 2003; 33(Suppl 2):23-30
4 Schaeffeler E, SchwabM, Eichelbaum M, Zanger UM.CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR[J]. Hum Mutat, 2003;22(6):476-85
5 Kitada M.Genetic polymorphism of cytochrome P450 enzymes in Asian populations:focus on CYP2D6[J]. Int J Clin Pharmacol Res, 2003;23(1):31-5
6 Charlier C, Broly F, Lhermitte M, Pinto E, AnsseauM, Plomteux G.Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine[J]. Ther Drug Monit, 2003;25(6):738-42
7 Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP).In vivo studies inWistar and Dark Agouti rats as well as in vitro studies in human liver microsomes[J]. Biochem Pharmacol, 2004;67 (2):235-44
8 Matoh N, Tanaka S, Takehashi M, Banasik M, Stedeford T, Masliah E, et al. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells [J]. Gene Expr, 2003;11(3-4):117-24
9 Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline[J]. Hum Psychopharmacol, 2004;19(1):17-23
10 Juan A, Carrillo, Sara I, Ramos, Jose AG. Agundez, et al. Analy sis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A[J]. Ther Drug Monit, 1998;20(3):319-24
11 Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, et al. Effects of cytochrome b(5)on drug oxidation activities of human cytochrome P450 (CYP)3As:similarity of CYP3A5 with CYP3A4 but not CYP3A7[J]. Biochem Pharmacol, 2003; 66(12):2333-40
12 Rosenbrock H, Hagemeyer CE, Ditter M, Knoth R, Volk B. Identification, induction and localization of cytochrome P450s of the 3A-subfamily in mouse brain[J]. Neurotox Res, 2001;3 (4):339-49
13 Torimoto N, Ishii I, HataM, Nakamura H, Imada H, Ariyoshi N, et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4[J]. Biochemistry, 2003;42(51):15068-77
14 Yamamoto T, Suzuki A, Kohno Y.High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method[J]. Xenobiotica, 2004; 34(1):87-101
15 Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J.Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates[J]. Chirality, 2004; 16(2):79-85
16 Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromy cin breath test predicts the clearance of midazolam[J]. Clin Pharmacol Ther, 1995;57(1): 16-24
17 Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB.Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients[J]. Clin Pharmacol Ther, 1992;52(5):471-8
18 Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root)on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004;75(1):89-100
19 Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, et al. The olivacine derivatives 16020 (9-hydroxy-5, 6-dimethyl-N-[2-(dimethylamino)ethyl]-6H-pyrido(4, 3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture [J]. Drug Metab Dispos, 2004; 32(1):80-8
20 Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease[J]. Circulation, 2004;109 (2):178-83
21 Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects[J]. Life Sci, 2004;74(7):827-34
22 Tanaka E, Kurata N, Yasuhara H. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes[J]. J Clin Pharm Ther, 2003;28(6):493-6
23 Spina E, Scordo MG, D' Arrigo C. Metabolic drug interactions with new psychotropic agents[J]. Fundam Clin Pharmacol, 2003;17(5):517-38
24 Benetton S, Kameoka J, Tan A, Wachs T, Craighead H, Henion JD.Chip-based P450 drug metabolism coupled to electrospray ionization-mass spectrometry detection[J]. Anal Chem, 2003;75(23):6430-6
25 Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P.Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function[J]. Clin Pharmacol Ther, 2004;75(1):80-8
26 Van Den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, Schellens JH. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol[J]. Invest New Drugs, 2004;22(2):151-8
27 Van Dijk KN, Plat AW, Van Dijk AA, Piersma-Wichers M, de Vries-Bots AM, Slomp J, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype[J]. Thromb Haemost, 2004; 91 (1):95-101
28 Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J]. Circulation, 2004; 109(2):166-71
29 孙霞, 吴葆杰, 张美.调血脂药物与肌病、横纹肌溶解症[J]. 中国药理学通报, 2003;19(2):130-3
30 王智勇, 彭仁秀, 张志喜.当归醇沉组分对肝CYP 同工酶的影响[J]. 现代中西医结合杂志, 2001; 10(11):1006-7
31 侯艳宁, 朱秀媛, 程桂芳.黄芩甙对小鼠肝细胞色素P450及其亚家族的诱导[J]. 解放军药学学报, 2000; 16(4): 68-71
32 杨秀芬, 王乃平, 曾繁典.中药有效成分对药物代谢酶的影响[J]. 中国中药杂志, 2002; 27(5):325-8
33 侯佩玲, 乔晋萍, 张瑞萍, 崔立杰, 再帕尔.阿不力孜, 等. 菊花提取物对大鼠肝微粒体细胞色素P450 的影响[J]. 中医药学报, 2003; 31(3):47-8
34 程泽能, 李焕德.化学药物与中药相关的相互作用[J]. 中国临床药理学杂志, 2002;18(1):74-7
35 Ueng YF, Kuo YH, Wang SY, Lin YL, Chen CF.Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL 6J but not in DBA 2J mice[J]. Life Sci, 2004;74(7):885-96
36 Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root)on cytochrome P450 activity in vivo[J]. Clin Pharmacol Ther, 2004;75(1):89-100
37 Le Bon AM, Vernevaut MF, Guenot L, Kahane R, Auger J, Arnault I, et al. Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats[J]. J Agric Food Chem, 2003;51(26):7617-23

[1]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[2]	HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
[3]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[4]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[5]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[6]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[7]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[8]	QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi. Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 429-437.
[9]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[10]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
[11]	WANG Wenjuan, QI Mingrui, TIAN Limin. Research progress on Nrf2 in diabetic cardiomyopathy and intervention of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1163-1170.
[12]	LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
[13]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[14]	ZHOU Han, LIU Xiaodong. Application of physiologically based pharmacokinetic model in drug development and several questions being thought [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
[15]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.